- Trial phase
- Unknown, not found in any clinical trial registry or pipeline disclosure.
- Time to market
- Unknown, ARGX-118 cannot be identified in any public source. If it was a preclinical program, it would be years from potential approval, if pursued at all.
- Why 1/10
- No catalyst is identifiable for ARGX-118 because the drug candidate does not appear in any public database, clinical trial registry, SEC filing, or press release. Without a known development stage or upcoming readout, the impact score defaults to the lowest tier.
ARGX-118 could not be identified in any available public database or internal source. Investors should verify the correct drug code, argenx's known pipeline includes ARGX-117 (complement inhibitor, Phase 2 completed), ARGX-119 (ALS, Phase 2 terminated), and approved VYVGART/efgartigimod. If ARGX-118 is a preclinical or discontinued program, it has no near-term catalyst value.
Price Chart
Executive Summary
ARGX-118 is a drug code that could not be identified in any available public database, clinical trial registry, SEC filing, press release, or internal SecBot data source. argenx SE (Nasdaq: ARGX) is a well-established immunology company with approved drug VYVGART (efgartigimod) and known pipeline candidates ARGX-117 (complement inhibitor, Phase 2 completed) and ARGX-119 (ALS, Phase 2 terminated), but ARGX-118 is absent from all records. It may be a preclinical program that was discontinued, renamed, or never publicly disclosed.
How It Works
Unknown. ARGX-118's mechanism of action cannot be determined from any available source. argenx specializes in antibody-based therapies for autoimmune diseases, with its core platform targeting the FcRn receptor (efgartigimod/VYVGART) and complement system (ARGX-117/empasiprubart). ARGX-118 may have been an early-stage discovery program in a similar immunology area, but no public information confirms this.
Trial Status
No clinical trial data available. ARGX-118 does not appear on ClinicalTrials.gov or in any argenx pipeline disclosure accessible through available databases.
The Two-Sided Case
Upcoming Catalysts
- None identifiable for ARGX-118. For argenx broadly: upcoming Phase 3 myositis readout for efgartigimod (completed July 2026, results pending), Phase 3 multifocal motor neuropathy readout for empasiprubart (primary completion Sept 2026).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARGENX SE 6-K ARGX ·Originating report